RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecif…
Author: Business Wire
Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa
BERKELEY, Calif.–(BUSINESS WIRE)–Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, today announced that the U.S. Food and Drug Administration (FD…
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
SAN FRANCISCO–(BUSINESS WIRE)–Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
Science Corp. Appoints Murat Günel, MD, as Medical Director for Brain-Computer Interfaces
ALAMEDA, Calif.–(BUSINESS WIRE)–Science Corporation, the full-stack neural engineering and brain-computer interface (BCI) company focused on restoring and extending life, today announced the appointment of Murat Günel, MD, as Medical Director for Bra…
Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
MightyMeals CEO Stefano Marzano Reunites with Children's National Doctor Who Helped Restore His Vision
WASHINGTON–(BUSINESS WIRE)–MightyMeals CEO and Executive Chef Stefano Marzano recently reunited with Dr. Marijean Miller of Children’s National Hospital, the ophthalmologist who treated him from infancy through age 18 after he was born blind—a moment…
Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced final 20-week study completion data from its randomized, head-to-head Phase 1…
YUVEZZI™ from Tenpoint Therapeutics, Ltd. Is Now Available Nationwide Across the United States
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-stage ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that YUVEZZI™ (carbachol an…
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The…
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive top…
Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
BENGALURU, India–(BUSINESS WIRE)–Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the Nomination &…
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics publie ses résultats financiers consolidés estimés pour l’année 2025
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodé…
Long Bridge Medical Receives Clearance from FDA to Initiate the U.S. Pivotal Clinical Study for LensOne Prosthetic Capsular Bag
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Long Bridge Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared initiation of its Investigational Device Exemption (IDE) study for LensOne™, the company’s prosthetic c…
Drug Farm Announces U.S. FDA Orphan Drug Designation for DF-003 for the Treatment of ROSAH Syndrome
ALBANY, N.Y. & SHANGHAI–(BUSINESS WIRE)–Drug Farm today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DF-003, the company’s investigational small molecule inhibitor targeting ALPK1, for the tr…
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious med…
Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive subgroup analyses from th…
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of …
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of …